Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Takeda Pharmaceutical Company Limited    4502   JP3463000004

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report  
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Takeda Sells Eye Drug to Novartis -- WSJ

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/09/2019 | 02:48am EDT

By Maria Armental

Takeda Pharmaceutical Co., looking to pay down debt following its megadeal for Shire PLC and narrow its focus, is selling eye drug Xiidra to Novartis AG and TachoSil surgical patches and sealants to Johnson & Johnson's Ethicon.

The deals, expected to close in the second half of the year, would bring Takeda $3.8 billion in cash up front and up to $1.9 billion in additional payments from Novartis subject to certain milestones being met, the companies said Wednesday.

Japan's Takeda has said it would sell about $10 billion worth of assets to pay down debt.

Xiidra, which Takeda acquired as part of its January purchase of drugmaker Shire, generated about $400 million in revenue last year and is seen as a potential blockbuster drug. It competes with Allergan PLC's No. 2 selling drug Restasis, which generated nearly $1.3 billion in sales in 2018, much of which came from the U.S.

The eye-drop solution for dry-eye disease is approved for sale in the U.S., Canada and Australia and under regulatory review in additional markets.

As part of the agreement, about 400 workers associated with Xiidra in the U.S. and Canada would join Novartis, the company said.

Bloomberg reported earlier Wednesday that Novartis was considering a bid for Xiidra.

As part of the deal with J&J, about 90 workers would join Ethicon. But Takeda would continue to own a manufacturing site in Linz, Austria, and make the TachoSil products for Ethicon under a long-term agreement, Takeda said.

TachoSil generated about $155 million in sales in the year ended March 31, 2018, Takeda said.

Takeda is scheduled to report financial results for the most recent year next week.

Moody's Investors Service and S&P Global Ratings have cut Takeda's credit ratings, citing a heavy debt load following the company's Shire deal. Both firms said the deal drove a ratio of debt to earnings well above that of pharmaceutical peers.

The company said Wednesday it is seeking to lower its debt-to-earnings ratio in the medium term.

Write to Maria Armental at maria.armental@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
ALLERGAN PLC 0.64% 173.6 Delayed Quote.29.88%
JOHNSON & JOHNSON -6.22% 127.7 Delayed Quote.-1.05%
NOVARTIS -0.73% 85.51 Delayed Quote.15.95%
TAKEDA PHARMACEUTICAL COMPANY LIMITED -1.28% 3780 End-of-day quote.4.42%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TAKEDA PHARMACEUTICAL COMP
01:02aTAKEDA PHARMACEUTICAL : Retrospective Real-World Comparative Analysis Highlights..
BU
10/15Takeda sells Mideast, Africa drug portfolio to Switzerland's Acino
RE
10/15TAKEDA PHARMACEUTICAL : Agrees to divest select otc and non-core assets to acino..
PU
10/01TAKEDA PHARMACEUTICAL : Working Mother Names Takeda as One of the 2019 100 Best ..
AQ
09/27TAKEDA PHARMACEUTICAL : New Data Presented at World Sleep Congress Demonstrate E..
AQ
09/27TAKEDA PHARMACEUTICAL : New Data Presented at World Sleep Congress Demonstrate E..
AQ
09/27TAKEDA PHARMACEUTICAL CO LTD : Ex-dividend day for interim dividend
FA
09/25TAKEDA PHARMACEUTICAL : New Data Presented at World Sleep Congress Demonstrate E..
BU
09/25TAKEDA PHARMACEUTICAL : First Head-to-Head Biologic Study in Ulcerative Colitis ..
BU
09/25EVOTEC : and Takeda enter collaboration agreement to discover clinical candidate..
AQ
More news
Financials (JPY)
Sales 2020 3 327 B
EBIT 2020 -47 541 M
Net income 2020 -292 922 M
Debt 2020 4 304 B
Yield 2020 4,76%
P/E ratio 2020 -20,1x
P/E ratio 2021 38,2x
EV / Sales2020 3,06x
EV / Sales2021 2,93x
Capitalization 5 891 B
Technical analysis trends TAKEDA PHARMACEUTICAL COMP
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Average target price 5 305,38  JPY
Last Close Price 3 780,00  JPY
Spread / Highest target 66,7%
Spread / Average Target 40,4%
Spread / Lowest Target -2,12%
EPS Revisions
Managers
NameTitle
Christophe Weber President, CEO & Representative Director
Costa Saroukos Chief Financial Officer
Andrew S. Plump Director, Chief Medical & Scientific Officer
Yasuhiko Yamanaka Director
Masato Iwasaki Director & President-Japan Pharma Business Unit
Sector and Competitors
1st jan.Capitalization (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED4.42%54 291
JOHNSON & JOHNSON5.52%337 021
ROCHE HOLDING AG18.49%250 869
MERCK AND COMPANY10.82%216 813
PFIZER-16.47%201 662
NOVARTIS15.95%198 751